Cargando…

The off-label use of targeted therapies in sarcomas: the OUTC’S program

BACKGROUND: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eberst, Lauriane, Cropet, Claire, Le Cesne, Axel, Pautier, Patricia, Penel, Nicolas, Adenis, Antoine, Chevreau, Christine, Bay, Jacques-Olivier, Collard, Olivier, Cupissol, Didier, Duffaud, Florence, Gentet, Jean-Claude, Piperno-Neumann, Sophie, Marec-Berard, Perrine, Bompas, Emmanuelle, Thyss, Antoine, Chaigneau, Loic, Cassier, Philippe, Bertucci, François, Blay, Jean-Yves, Ray-Coquard, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289372/ https://www.ncbi.nlm.nih.gov/pubmed/25420707 http://dx.doi.org/10.1186/1471-2407-14-870

Ejemplares similares

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
por: Penel-Page, Mathilde, et al.
Publicado: (2015)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
por: Huynh, Thanh-Khoa, et al.
Publicado: (2014)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
por: Pautier, P., et al.
Publicado: (2021)

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
por: Rochefort, Pauline, et al.
Publicado: (2017)

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

From rare to well-done: importance of rare tumors in cancer therapeutic advances
por: Duffaud, Florence, et al.
Publicado: (2019)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Recent advances in understanding and managing leiomyosarcomas
por: Duffaud, Florence, et al.
Publicado: (2015)

Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
por: Kubicek, Pierre, et al.
Publicado: (2023)

Determinants of the access to remote specialised services provided by national sarcoma reference centres
por: Fayet, Yohan, et al.
Publicado: (2021)

Desmoplastic Small Round Cell Tumor: Current Management and Recent Findings
por: Dufresne, Armelle, et al.
Publicado: (2012)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
por: Cassier, P A, et al.
Publicado: (2013)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
por: Bouché, Olivier, et al.
Publicado: (2018)

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020)

Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
por: Brahmi, Mehdi, et al.
Publicado: (2022)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
por: Debaudringhien, M., et al.
Publicado: (2022)

Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
por: Penel, Nicolas, et al.
Publicado: (2009)

OUTC-02. CASE SERIES OF HYPERMUTATED PEDIATRIC CNS TUMORS
por: Parisi, Rose, et al.
Publicado: (2023)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
por: Penel, Nicolas, et al.
Publicado: (2020)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study
por: Tabone, Marie-Dominique, et al.
Publicado: (2017)

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

OUTC-05. DIFFERENCES IN FACTORS INFLUENCING SURVIVAL IN CHILDHOOD AND ADULT CNS MALIGNANCIES
por: Matharoo, Jashanjeet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jloo41406pk0hgjv205rt053b3